To include your compound in the COVID-19 Resource Center, submit it here.

AZ, Merck ink $8.5B PARP and MEK inhibitor deal

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Merck & Co. Inc. (NYSE:MRK) partnered to co-develop and co-commercialize AZ’s PARP inhibitor Lynparza olaparib worldwide for multiple tumor types in a deal worth up to $8.5 billion. The deal also includes the joint development of AZ’s selumetinib (ARRY-886, AZD6244), a

Read the full 466 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers